INMB
INmune Bio, Inc.
There isn't enough reported data to score INMB yet.
INMB Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
INMB's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
INMB PE Valuation
INMB has no meaningful PE right now: it lost money over the past year.
INMB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect INMB's revenue to decline, with its earnings and profitability holding steady.
INMB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.56 | +$1.56 |
| Q2 2026 | -$0.63 | +$1.85 |
| Q1 2026 | -$1.63 | +$0.30 |
| Q4 2025 | -$1.86 | +$0.25 |
| Q3 2025 | -$2.12 | +$0.06 |
| Q2 2025 | -$2.48 | -$0.42 |
| Q1 2025 | -$1.93 | -$0.01 |
| Q4 2024 | -$2.11 | -$0.44 |
INMB is still losing money, but far less than before: $0.56 per share over the past year, against $2.48 at its worst in mid-2025.
INMB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2025 | $50K | +257% |
| Q1 2024 | $14K | -63% |
| Q4 2023 | $28K | -71% |
| Q3 2023 | $43K | -56% |
| Q2 2023 | $46K | +188% |
| Q1 2023 | $38K | -77% |
| Q4 2022 | $97K | -40% |
| Q3 2022 | $98K | +600% |
INMB's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | -19810% | +58883 points |
| Q1 2024 | -78693% | -61790 points |
| Q4 2023 | -29925% | -24109 points |
| Q3 2023 | -19833% | -12238 points |
| Q2 2023 | -13937% | +25988 points |
| Q1 2023 | -16903% | -12928 points |
| Q4 2022 | -5816% | -277 points |
| Q3 2022 | -7595% | +56841 points |
INMB's operating margin was −19810% last quarter, down 5873 points from the same quarter a year ago.
INMB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.4M | +$2.2M |
| Q1 2026 | -$3.4M | +$3.4M |
| Q4 2025 | -$3.1M | +$7.9M |
| Q3 2025 | -$5.6M | +$1.4M |
| Q1 2025 | -$6.8M | +$652K |
| Q4 2024 | -$11M | -$7.6M |
| Q3 2024 | -$7M | -$2.7M |
| Q2 2024 | -$7.9M | -$4.7M |
INMB has burned cash in almost every quarter: −$13M over the past year, against −$30M the year before.
INMB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.1% | +1.1M shares |
| 1 year | +4.6% | +1.2M shares |
| 3 years | +54% | +9.8M shares |
| 5 years | +60% | +10.5M shares |
| Available history | +171% | +17.5M shares |
INMB has 28M diluted shares, up 4.6% from a year ago.
INMB Net Leverage
INMB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
INMB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.4 | Neutral |
| Stochastic | 3.7 | Oversold |
INMB's weekly RSI is 32 (neutral) and its Stochastic is 4 (oversold).
INMB PE vs Healthcare Sector
INMB has no meaningful PE right now: it lost money over the past year.
INMB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.56 | 33% below |
| 20 week MA | $1.87 | 44% below |
| 50 week MA | $1.63 | 36% below |
| 100 week MA | $3.33 | 68% below |
| 200 week MA | $5.90 | 82% below |
INMB is in a downtrend: it's below all five of its weekly moving averages, and 82% below its 200-week average.
INMB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.35 | $12.8 | +138% |
| 2021 | $12.8 | $10.9 | -15% |
| 2022 | $10.9 | $7.03 | -35% |
| 2023 | $7.03 | $11.3 | +60% |
| 2024 | $11.3 | $4.65 | -59% |
| 2025 | $4.65 | $1.73 | -63% |
| 2026 YTD | $1.73 | $1.05 | -39% |
INMB's yearly returns have swung widely, from +138% in 2020 to −63% in 2025. It's down 39% so far in 2026.